Clinical and Morphological Characteristics of Anti–Programmed Death Ligand 1–Associated Retinopathy
- 15 November 2019
- journal article
- research article
- Published by Elsevier BV in Ophthalmology Retina
- Vol. 4 (4), 446-450
- https://doi.org/10.1016/j.oret.2019.11.006
Abstract
No abstract availableKeywords
Funding Information
- Macula Foundation
This publication has 14 references indexed in Scilit:
- Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal VenulitisJAMA Ophthalmology, 2019
- Immune checkpoint inhibitors: recent progress and potential biomarkersExperimental & Molecular Medicine, 2018
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumabLung Cancer, 2018
- Checkpoint inhibitor-induced uveitis: a case seriesAlbrecht von Graefes Archiv für Ophthalmologie, 2017
- Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral TherapyThe Journal of Infectious Diseases, 2017
- Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitisProceedings of the National Academy of Sciences of the United States of America, 2017
- Acute macular neuroretinopathy: A comprehensive review of the literatureSurvey of Ophthalmology, 2016
- ACUTE MACULAR NEURORETINOPATHYRetina, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011